Starling Oncology Institute Inc (STLN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2025 | 12-2024 | 09-2024 | 06-2024 | 03-2024 | |
| Sales | 104,406 | 100,267 | 99,901 | 98,578 | 94,666 |
| Cost of Goods | 87,157 | 85,631 | 85,535 | 85,552 | 82,697 |
| Gross Profit | 17,249 | 14,636 | 14,366 | 13,026 | 11,969 |
| Operating Expenses | 27,317 | 27,196 | 28,754 | 29,942 | 30,638 |
| Operating Income | -9,911 | -11,929 | -13,853 | -16,364 | -17,972 |
| Interest Expense | 5,570 | 1,168 | 2,225 | 2,118 | 1,985 |
| Other Income | -4,104 | -85 | -35 | 3,003 | 68 |
| Pre-tax Income | -19,585 | -13,182 | -16,113 | -15,479 | -19,889 |
| Net Income Continuous | -19,585 | -13,182 | -16,113 | -15,479 | -19,889 |
| Net Income | $-19,585 | $-13,182 | $-16,113 | $-15,479 | $-19,889 |
| EPS Basic Total Ops | -0.21 | -0.14 | -0.18 | -0.17 | -0.22 |
| EPS Basic Continuous Ops | -0.25 | -0.17 | -0.21 | -0.21 | -0.27 |
| EPS Diluted Total Ops | -0.21 | -0.14 | -0.18 | -0.17 | -0.22 |
| EPS Diluted Continuous Ops | -0.25 | -0.17 | -0.21 | -0.21 | -0.27 |
| EPS Diluted Before Non-Recurring Items | -0.18 | -0.14 | -0.18 | N/A | N/A |
| EBITDA(a) | $-3,253 | $-8,629 | $-10,741 | $-13,408 | $-15,248 |